Progress ReportThe ItalianSocietyofGastroenterology(SIGE)andtheItalianGroupforthestudyof InflammatoryBowelDisease(IG-IBD)ClinicalPracticeGuidelines:The useoftumor necrosisfactor-alphaantagonisttherapyinInflammatoryBowelDisease

Mario Cottone, Livia Biancone, Anna Kohn, Paolo Gionchetti, Fernando Rizzello, Claudio Papi, Alessandro Armuzzi, Gilberto Poggioli, Aurora Bortoli, Renata D'Incà, Fabiana Castiglione, Sandro Ardizzone, Paolo Gionchetti, Vito Annese, Maurizio Vecchi

Risultato della ricerca: Articlepeer review

109 Citazioni (Scopus)

Abstract

Biological therapiesareanimportantstepinthemanagementofInflammatoryBowelDiseases.Incon-sideration ofhighcostandsafetyissuesthereistheneedtohaveclearrecommendationsfortheiruse.Despite theAmericanGastroenterologicalAssociationandtheEuropeanCrohn’sandColitisOrganisationhave publishedexhaustiveInflammatoryBowelDiseaseguidelines,nationalguidelinesmaybeneces-sary asculturalvalues,economicalandlegalissuesmaydifferbetweencountries.ForthesereasonstheItalian SocietyofGastroenterologyandtheItalianGroupforthestudyofInflammatoryBowelDiseasehave decidedtoelaboratetheItalianguidelinesontheuseofbiologicsinInflammatoryBowelDisease.The followingitemshavebeenchosen:definitionsofactive,inactive,steroiddependentandresistantdisease; measuresofactivity;anti-tumornecrosisfactoralphatherapyuseinactivesteroiddependentand refractoryluminalCrohn’sDisease,infistulisingCrohn’sDisease,insteroiddependentandresistantactive UlcerativeColitis;riskofcancer;riskofinfectionsduringanti-tumornecrosisfactoralphatherapy;special situations.Theseguidelinesarebasedonevidencefromrelevantmedicalliteratureandclinicalexperience ofanationalworkinggroup.
Lingua originaleEnglish
pagine (da-a)1-20
Numero di pagine21
RivistaDigestive and Liver Disease
Volume43
Stato di pubblicazionePublished - 2011

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cita questo